COVID-19 Situation Report – 1 May 2020

1. Situation Overview

Global cases: 3,145,407 confirmed. Global deaths: 221,823 confirmed. Countries, areas or territories with cases: 214 (as of 1 May, WHO). WHO has published technical guidance titled ‘Strengthening Preparedness for COVID-19 in Cities and Urban Settings’. The WHO Information Network for Epidemics (EPI-WIN) has rapidly built an analysis capability to identify misleading sources, posts and narratives. WHO has published the ‘R&D Blueprint: COVID-19 Experimental Treatments’, which lists drug and non-drug experimental treatments for COVID-19. WHO has called on countries to ensure that usual immunization is maintained wherever possible and surveillance for vaccine-preventable diseases is not disrupted during the ongoing pandemic. The Global Fund is coordinating with the WHO, which is leading the global response. WHO Situation Reports have detailed updates.

2. Global Fund COVID-19 Response

The Global Fund is providing up to US$1 billion and operational flexibility to help countries fight COVID-19, shore up health systems and mitigate the impacts on lifesaving HIV, TB and malaria programs. Emergency funding is available through the US$500 million COVID-19 Response Mechanism and additional grant flexibilities of up to US$500 million (Español | Français). Latest updates:

- Funding has been approved for 72 countries and five regional grants (171 individual decisions) for a total of nearly US$108 million. The full list of countries and funding approved is available here. All requests follow WHO guidance on preparedness and early response. Additional funding requests are in preparation.
- More than half of all countries implementing Global Fund grants are now using the COVID-19 grant flexibilities.
- Source of funds almost exclusively from savings from existing grants (97%), thus no negative impact on ongoing Global Fund-supported programs.


Business Contingency Planning focuses on protecting the Global Fund’s ability to deliver its core mission, prioritizing the continued delivery of impact from the current grant cycle and the development of funding requests and grants to deliver maximum impact in the 2020-2022 allocation period.

3.1 2020-2022 Allocations

- To provide additional flexibility for applicants to submit funding requests as soon as they are ready, the Global Fund has updated the funding request submission dates for 2020.

3.2 Operational Guidance for Countries

- The Global Fund is adapting processes for current grants and will share guidance notes as they are developed. Please visit our website for updates.
- Application materials for the COVID-19 Response Mechanism are available here.
3.3 COVID-19 Impact on HIV, TB, Malaria, Communities, Rights and Gender

- WHO and technical partner guidance relevant to Global Fund work is available [here](#).
- Global Fund COVID-19 Information Notes: Global Fund investments and advice to Principal Recipients and implementers strictly follow WHO guidelines. Global Fund COVID-19 Information Notes on HIV, TB, malaria, health systems and human rights are available [here](#).

3.4 Procurement and Supply Chain

- As of 24 April 2020, the Global Fund’s product and delivery outlook shows the overall impact of COVID-19 on health product supply chains for Global Fund grants remains at moderate.
- Today, 8% of Pooled Procurement Mechanism face delays of more than 30 days, including 14% of orders in transit. We now have volume visibility for most deliveries expected in 2020 which enables us to manage expectations, minimize delays and facilitate timely support to Principal Recipients and Country Teams to the extent possible.
- Together with partners and Governments, we are participating in the WHO-led Access to COVID Tools Accelerator (ACTA) to support increasing access to COVID health products and bringing together supply chain expertise on end-to-end procurement processes. We’re negotiating production capacity with key diagnostics suppliers and will work with WHO, UNICEF and other members of the consortium to ensure equitable access to the available supply.
- The Global Fund is operationalizing procurement by channeling demand from low- and middle-income countries. We will leverage existing technologies, such as wambo.org, to bring the needed products and catalogues online so new catalogues so countries can rapidly purchase COVID-19 health products consistent with our current processes for all Principal Recipients.

4. Messaging and Advocacy

- **COVID-19 Key Messages and Talking Points**: updated regularly.
- The Global Fund is working closely with partners and suppliers to minimize disruption to the production and availability of lifesaving supplies for the fight against HIV, TB and malaria during the COVID-19 pandemic. We are deeply concerned about any action that might reduce the availability of tests or treatment for HIV, TB or malaria. Given the risk that COVID-19 undermines our continued progress in the fight against existing epidemics, this is not the time to be doing anything that weakens our ability to diagnose and treat those infected with HIV, TB and malaria in a timely and cost-effective way. Doing so would cost lives.

5. Media and Communications

- **Short case studies** of countries responding to COVID-19 using support from the Global Fund are available. Additional stories and case studies will be added as available.
- **Video: Unite to Fight Against COVID-19 and HIV, TB and Malaria** (aussi en [français](#))
- **Unite to Fight social media tiles** are available in English, French, Spanish, German and Italian.
- **In the news:**
  - [Demand for Coronavirus Tests Raises Concerns over HIV And Malaria](#), The Guardian – UK, By Sarah Boseley, 01 May 2020
  - [Coronavirus in Africa](#), Financial Times Podcast featuring Donald Kaberuka, 30 April 2020.
6. External Coordination

- The Global Fund and partners will participate in the Coronavirus Global Response International Pledging Event hosted by the European Union on 4 May 2020 to raise €7.5 billion in initial funding for the global response.
- On 24 April 2020, the Global Fund joined WHO, Gavi the Vaccine Alliance, Unitaid and other global health and private sector partners to launch the Access to COVID-19 Tools (ACT) Accelerator to call for increased collaboration to accelerate the development, production and equitable distribution of vaccines, diagnostics, and therapeutics for COVID-19.
- The Global Fund continues to work closely with WHO and global health partners at global, regional and country levels on COVID-19 preparedness and response, particularly key issues such as supply chain, technical guidance and in-country coordination.
- The Global Fund is participating in a WHO-led consortium on procurement with public and private sector partners to help deliver health products to countries in need.
- The Global Fund is closely collaborating with numerous governments and organizations including the World Bank; Gavi, the Vaccine Alliance; many UN agencies; the Africa CDC; as well as private sector manufacturers, to advance a global response.

7. Key Resources

- Global Fund COVID-19 Response web page
- WHO Coronavirus disease (COVID-19) Pandemic web page